Abstract
We prospectively monitored 61 allogeneic BMT patients for evidence of CMV infection and disease starting 7 days prior to transplant until day 110 after transplant. Patients receiving pre- and post-transplantation ganciclovir prophylaxis were followed for the incidence of infection by the CMV antigenemia assay and shell vial cultures. The median age of all patients was 32 years (range 5–54 years). Fourteen (25%) of 57 evaluable patients became CMV antigenemia or culture positive. The incidence of culture or antigenemia positivity in CMV seropositive or seronegative patients with a seropositive donor was 29% (14 of 49 patients). The antigenemia assay became positive a median of 29 days (range 12–89 days) after BMT as compared to 46 days (range 26–98 days) by shell vial assay (P < 0.001). there were no cases of cmv disease in the first 110 days after transplant. this study demonstrates that despite the use of prophylactic ganciclovir, bmt patients developed cmv infection but did not progress to disease in this study, the cmv antigenemia assay may be used to monitor for cmv infection during prophylaxis, and the current regimens for cmv prophylaxis with ganciclovir may require further evaluation to determine an optimal regimen to prevent cmv infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nicholson, V., Whimbey, E., Champlin, R. et al. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Bone Marrow Transplant 19, 37–41 (1997). https://doi.org/10.1038/sj.bmt.1700612
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700612
Keywords
This article is cited by
-
Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT
Bone Marrow Transplantation (2011)
-
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
Bone Marrow Transplantation (2007)
-
Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
Bone Marrow Transplantation (2007)
-
Diagnosis and monitoring of primary cytomegalovirus infection by antigenemia test
Bone Marrow Transplantation (2002)
-
A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy
Bone Marrow Transplantation (2000)